Action A new addition to the synthetic oligosaccaride family of anticoagulant drugs. Indicated for the treatment and secondary prevention of VTE.
Status In phase III development.
Trial(s) = Ongoing = Completed
UID: 196
Internet Stroke Center at Washington University: HOME | ABOUT | PRIVACY POLICY | CONTACT
Copyright © 1997-2010 - Internet Stroke Center. All rights reserved. Last modified: Friday, March 12, 2010